StockNews.AI
ANIX
StockNews.AI
162 days

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

1. Anixa will hold its 2025 Annual Meeting on March 20, 2025. 2. CEO Dr. Amit Kumar will provide a corporate update post-meeting. 3. Anixa focuses on innovative cancer treatments in collaboration with top institutions. 4. Their technology includes advanced CAR-T and cancer vaccines under clinical development. 5. Forward-looking statements caution about uncertainties affecting future performance.

5m saved
Insight
Article

FAQ

Why Bullish?

The scheduled meeting and investor presentation could enhance shareholder confidence, similar to past successful updates which positively influenced stock prices in biotech firms. For example, the announcement of positive trial results often led to immediate gains in stock value for similar companies.

How important is it?

The information about the annual meeting and corporate updates is significant for investors, driving potential trading activity but lacking immediate groundbreaking news.

Why Short Term?

The upcoming investor presentation is expected to have an immediate effect on market perception, as stakeholders tend to respond to direct communication from company leadership during significant meetings.

Related Companies

Moffitt Cancer CenterCleveland Clinic
SAN JOSE, Calif., March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2025 Annual Meeting of Stockholders (the "Meeting") on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time in a virtual format. Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a question-and-answer session. All interested parties may attend the Meeting. All parties may access the Meeting online at www.virtualshareholdermeeting.com/ANIX2025. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFO[email protected]408-708-9808 SOURCE Anixa Biosciences, Inc.

Related News